Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
Oncimmune is not the only company looking to use the immune system to diagnose cancer. But its growth plans are intense, and it intends to prove the economic benefits of…
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.
Guardant gets a liquid biopsy trial win, but if it wants to drive sales it must get cancer societies on board.